Syrosingopine enhances immune checkpoint blockade efficacy by inhibition of MCTs and metabolic reprogramming in triple-negative breast cancer
{{output}}
Immune checkpoint blockade (ICB) provides limited benefit in triple-negative breast cancer (TNBC), partly due to a lactate-rich, immunosuppressive tumor microenvironment (TME). Integrative bulk and single-cell transcriptomics, corroborated by tissue analyses, ... ...
